.webp?width=217&height=60&name=Screenpoint-Med%20(1).webp "Screen Point Medical")
ScreenPoint Medical highlights Transpara at ECR 2026
By ScreenPoint Insights on February 23, 2026
ScreenPoint Medical is proud to return to the European Congress of Radiology, held this year in Vienna, Austria from March 4–7. Join us at Booth D-16 (Expo Foyer D, Level -2) to explore how the Transpara® Breast AI Suite supports breast cancer screening through improved accuracy, workflow efficiency, and risk stratification.
ScreenPoint Medical’s presence offers radiologists and healthcare leaders the chance to learn, connect, and explore:
- Learn more about the Transpara® Breast AI Suite: ScreenPoint Medical will offer personalized demos of its best-in-class solutions: Detection, Density, and Temporal Comparison. These tools are designed to assist radiologists in identifying subtle malignancies and managing screening workloads.
- Scientific sessions offer key context: Backed by robust clinical evidence, Transpara Breast AI leads the competition and delivers for clients. Transpara is the subject of key sessions, including:
- MASAI RCT Results: Two sessions highlight the final research takeaways from the landmark MASAI randomised controlled trial, showing how Transpara helps radiologists focus on high-risk cases and reduces interval cancers. (Thursday, March 5 at 1630 CET, RPS-1102-1 and RPS-1102-2, M-Building, Research Stage 2)
- AIMS RCT Update: A discussion of the large-scale randomised trial evaluating Transpara-supported mammography in Norway. (Thursday, March 5 at 1630 CET, RPS-1102-3, M-Building, Research Stage 2)
- Risk Prediction: New research shows Transpara’s superior performance in five-year breast cancer risk prediction compared to traditional epidemiological models. (Friday, March 6 at 1230 CET, RPS-1402-7, M-Building, Research Stage 6)
- And many more.
- MASAI RCT Results: Two sessions highlight the final research takeaways from the landmark MASAI randomised controlled trial, showing how Transpara helps radiologists focus on high-risk cases and reduces interval cancers. (Thursday, March 5 at 1630 CET, RPS-1102-1 and RPS-1102-2, M-Building, Research Stage 2)
- Expert Access: Co-founder and researcher Professor Nico Karssemeijer as well as VP of Clinical Innovation Alejandro Rodriguez-Ruíz will be on-site to discuss real-life cases, implementation strategies, and the latest research.
Our team looks forward to seeing you onsite and in person.
View all scientific sessions and schedule your personalized demo here.